GRI Bio Inc is a clinical-stage biotech company focused on discovering, developing, and commercializing therapies targeting serious diseases associated with dysregulated immune responses that to inflammatory, fibrotic, and autoimmune disorders. GRI Bio's program, GRI-0621, is a small molecule RAR-beta and gamma dual agonist that inhibits the activity of human NKT I cells, returning the immune system to homeostasis. It is also an oral formulation of tazarotene, a synthetic RAR-beta and gamma selective agonist for the topical treatment of psoriasis and acne. The company's other product candidate GRI-0803 is a novel oral agonist of type 2 Natural Killer T (type 2 NKT) cells which can be a potential treatment for autoimmune disorders.
Last trade$0.00
Day change$0.00 (0.00%)
Day range$1.39 – $1.53
Volume22,127
Market cap$3M
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$3.06M
Price / earnings
—
Price / book
0.35×
Price / sales
—
EV / sales
—
EV / EBITDA
0.82×
Profitability
Earnings per share
-$3.57
Return on assets
-79.98%
Return on equity
-88.63%
Dividend yield
0%
Liquidity and leverage
Debt / equity
0×
Current ratio
10.21×
Quick ratio
10.21×
Cash ratio
9.94×
Cash flow
Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$9.58M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for GRI, quarterly periods
Line item
Q3 FY2026 Sep 30, 2026
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Revenue
$0
$0
$0
$0
$0
$0
$0
$0
Cost of revenue
$0
$0
$0
$0
$0
$0
$0
$0
Gross profit
$0
$0
$0
$0
$0
$0
$0
$0
Selling, general and administrative
$1.3M
$1.24M
$1.64M
$1.03M
$1.6M
$1.02M
$1.41M
$1.05M
Research and development
$212K
$407K
$361K
$1.63M
$1.77M
$1.88M
$1.64M
$907K
Total operating expenses
$1.51M
$1.65M
$2M
$2.66M
$3.37M
$2.9M
$3.05M
$1.95M
Operating income
-$1.51M
-$1.65M
-$2M
-$2.66M
-$3.37M
-$2.9M
-$3.05M
-$1.95M
Interest expense
$5K
$5K
$5K
$0
$6K
$5K
$5K
$0
Income before taxes
-$1.51M
-$1.64M
-$2M
-$2.66M
-$3.36M
-$2.89M
-$3.05M
-$1.95M
Income taxes
$0
$0
$0
$0
$0
$0
$0
$0
Net income
-$1.51M
-$1.64M
-$2M
-$2.66M
-$3.36M
-$2.89M
-$3.05M
-$1.95M
Net income attributable to common shareholders
-$1.51M
-$1.64M
-$2M
-$2.66M
-$3.36M
-$2.89M
-$3.05M
-$3.86M
EBITDA
-$1.51M
-$1.65M
-$2M
-$2.66M
-$3.36M
-$2.9M
-$3.05M
-$1.95M
Basic earnings per share
-$0.69
-$0.91
-$1.61
—
-$35.88
-$36.72
-$162.30
-$1.97
Diluted earnings per share
-$0.69
-$0.91
-$1.61
—
-$35.88
-$36.72
-$162.30
-$1.97
Recent news
Company coverage with links to the original publishers.
GRI Bio participated in a virtual investor segment discussing its Phase 2a study interim biomarker data for Idiopathic Pulmonary Fibrosis, highlighting potential therapeutic advances in treating inflammatory and fibrotic diseases using NKT cell modulators.
Windtree Therapeutics, a biotechnology company, announced the appointment of Leanne Kelly to its board of directors. Ms. Kelly has significant public company executive experience and will serve as an independent director and chair of the audit committee.
GRI Bio, a biotechnology company, announced that the European Patent Office has issued a decision to grant a patent for its NKT cell modulator GRI-0803 and its library of over 500 proprietary compounds. The company is focused on developing treatments for inflammatory, fibrotic, and autoimmune diseases.
GRI Bio, a biotechnology company, announced the exercise of existing warrants and the issuance of new warrants. The company intends to use the proceeds for working capital and general corporate purposes.
GRI Bio, a biotechnology company, announced that it will participate in the Virtual Investor Lunch Break Series on July 17, 2024, where the CEO will provide a corporate overview and business outlook.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
Ex-dividend
Amount / share
Pay date
Type
Dec 19, 2019
$22,147.0376
Dec 27, 2019
recurring
Sep 19, 2019
$11,716.1117
Sep 26, 2019
recurring
Jun 20, 2019
$16,137.3758
Jun 27, 2019
recurring
Mar 21, 2019
$15,005.9619
Mar 28, 2019
recurring
Dec 20, 2018
$17,733.5704
Dec 27, 2018
recurring
Stock splits
Historical share-structure events and their execution dates.